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Residual kidney function is important for patient and
technique survival in peritoneal dialysis (PD). Biocompatible
dialysis solutions are thought to improve function and
viability of peritoneal mesothelial cells and to preserve
residual renal function (RRF). We conducted a randomized
controlled study comparing use of biocompatible (B) with
standard (S) solutions in 93 incident PD patients during a
1-year period. The demographics, comorbidities, and RRF of
both groups were similar. At 3 and 12 months, 24-h urine
samples were collected to measure volume and the mean
of urea and creatinine clearance normalized to body surface
area. Surrogate markers of fluid status, diuretic usage,
C-reactive protein concentration, peritonitis episodes,
survival data, and peritoneal equilibrium tests were also
collected. Changes in the normalized mean urea and
creatinine clearance were the same for both groups, with
no significant differences in secondary end points. Despite
non-randomized studies suggesting benefits of these newer
biocompatible solutions, we could not detect any clinically
significant advantages. Additional studies are needed to
determine if advantages are seen with longer term use.
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It has been suggested that the bioincompatible nature of
conventional peritoneal dialysis (PD) solutions contributes
to the structural peritoneal membrane changes that lead to
deterioration in solute transport characteristics and loss of
ultrafiltration (UF).1 The in vitro use of neutral-pH low
glucose degradation product (GDP) solutions2 such as
Physioneal (Baxter Healthcare, Compton, UK) has been
shown to improve function and viability of the peritoneal
membrane3,4 and other cells associated with host defence.5,6
The South Korean registry data suggested that the use of
another ‘biocompatible’ (B) solution, Balance (Fresenuis, Bad
Homburg, Germany), conferred a survival advantage,
although PD technique and peritonitis rates were similar.7,8
Although the limitations of retrospective registry data were
acknowledged, it was proposed that preservation of residual
renal function (RRF) in patients using Balance might explain
the survival advantage. In support of this hypothesis,
reanalysis of the Canada-USA (CANUSA) Peritoneal Dialysis
Study data9 correlated patient survival with residual kidney
function, while the EuroBalance study10 demonstrated that
urine volume (Uvol) decreased after switching from the
biocompatible to the standard (S) solution. However, in the
EuroBalance study, it was not possible to determine if the
observed effect was related to short-term changes in fluid
balance (increased urine output related to hypervolemia) or
preservation of RRF.11
We conducted a prospective randomized controlled
open-labeled trial of incident patients starting PD to examine
changes in RRF (assessed by 24-h urine collection) over a
1-year follow-up. Secondary end points for this study
included the following:
K Peritonitis rate
K PD technique survival (censored for transplantation)
K Changes in peritoneal membrane function assessed by
peritoneal equilibrium test (PET)
K Biomarker of inflammation, C-reactive protein (CRP)
RESULTS
Study population
During the 2-year recruitment period from 1 January 2004 to
31 December 2005, 153 patients newly started PD at our
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institution. Informed consent was obtained from 118
patients. The remaining 35 patients were either unsuitable
for the study (patients were assessed and felt most suited to
the UV Compact System (Baxter Healthcare) for which
biocompatible equivalent solutions are unavailable) or
refused consent. There were 57 patients randomized to
receive biocompatible solutions (23 continuous ambulatory
peritoneal dialysis (CAPD) and 34 automated peritoneal
dialysis (APD)) and 61 were established on standard
solutions (24 CAPD and 37 APD). Of the CAPD patients,
five used StaySafe Balance and four used StaySafe Standard
solutions (Fresenius, Bad Homburg, Germany). All other
CAPD and all APD patients used solutions supplied by
Baxter. The demographics of these patients (Table 1) showed
no significant statistical differences for age, sex, proportion of
patients with diabetes mellitus, prior requirement for
hemodialysis (HD), ethnicity, and comorbidity (assessed by
the UK Renal Registry score and the Karnofsky score). There
were also no differences in serum creatinine concentration,
estimated glomerular filtration rate calculated by Cockcroft–-
Gault equation, and hemoglobin concentration at the time of
starting dialysis (censored for patients who started HD more
than 30 days before PD).
There were 44 patients randomized to biocompatible
solutions and 49 in the standard solution group that had two
sets of 24-h urine collection that allowed analysis for loss of
RRF over the study period. The reasons for dropout are listed
in Figure 1. Transplantation, technique failure, and death
were significant causes of dropout, but non-adherence to
request to complete and return 24-h urine collections was the
commonest cause. This occurred at a similar rate in both
Table 1 | Demographic and baseline details of study patients
Full analysis cohort Per protocol analysis cohort
Biocompatible Standard P-value Biocompatible Standard P-value
Number 57 61 44 49
Age (mean/s.d.) 51.6 (2.0) 54.5 (1.7) NS 53.9 (3) 54.2 (1.9) NS
% APD 59.6 60.7 NS 61.4 65.3 NS
Sex (% males) 66.7 63.9 NS 65.9 59.2 NS
% diabetes mellitus 26.3 31.1 NS 27.3 32.7 NS
HD prior to PD (n/mean days) 21/19.8 (6.3) 20/12.8 (3.6) NS 17/16.8 (5) 17/14.1 (4.4) NS
S UK Renal Registry
comorbidity score (mean)
0.72 (0.14) 0.80 (0.16) NS 0.73 (0.16) 0.82 (0.18) NS
Karnofsky score 80 (2) 81 (1) NS 79 (2) 81 (2) NS
Ethnicity (% Caucasian) 43.9 50.8 NS 43.2 49.0 NS
Parameters at the start of ESRF
Serum creatinine (mmol l) 835 (43) 858 (41) NS 826 (44) 867 (49) NS
eGFR (ml min1) 9.4 (0.7) 8.7 (0.4) NS 8.6 (0.5) 8.6 (0.4) NS
Hb (g dl1) 9.8 (0.3) 10.6 (0.3) NS 9.7 (0.3) 10.3 (0.3) NS
Cause of ESRF
Diabetic nephropathy 11 13 9 10
Chronic GN 7 13 5 11
Chronic pyelo/interstitial nephritis 6 5 6 4
APKD 4 4 3 3
Hypertension 8 7 2 5
Others 7 12 9 9
Unknown 14 7 10 7
Previous kidney transplant (n) 4 2 1 2
APD, automated peritoneal dialysis; APKD, adult polycystic kidney disease; eGFR, estimated glomerular filtration rate; GN, glomerulonephritis; HD, hemodialysis; NS, not
significant; PD, peritoneal dialysis.
Total starting PD between
1 January 2004 and 
153
Excluded (refused consent, 
or exclusion criteria): 35
Randomized: 118
Biocompatible
CAPD: 23
APD: 34
Standard
CAPD: 24
APD: 37
1 Transplantation: 2
2 Transfer to HD 3
1 Death 2
Missing 24 h urine collection
because:
44 Complete dataset for 49
9 Did not complete 5
31 December 2005
Figure 1 | Consort diagram showing the number of patients
recruited into the study and reasons for dropout.
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groups. The demographics of the ‘per protocol’ subsets were
similar (Table 1).
Residual renal function
Residual renal function for primary analysis was assessed
through 24-h urine collection. Uvol and the mean of urea
and creatinine clearance normalized to 1.73 body surface area
(BSA) (nCrCl) were measured. At 3 months after starting PD,
patients randomized to receive standard PD solutions had a
mean (7s.e.m.) Uvol of 1.070.1 l and a mean (7s.e.m.)
nCrCl of 54.275.4 l week1. The RRFs of patients who were
randomized to biocompatible solutions were as follows:
Uvol¼ 0.870.1 l and nCrCl¼ 51.476.2 l week1. There were
no intergroup statistical differences in the means of these
parameters.
The 24-h urine collection at 12 months for both groups
showed statistically significant intragroup reductions of both
nCrCl and Uvol (Figures 2 and 3), but there was no
intergroup difference. For the standard group, mean (s.e.m.)
Uvol reduction was 0.37 l day1 (0.10), while mean (s.e.m.)
nCrCl reduced by 15.9 nl week1 (0.35; both Po0.0001). The
group randomized to biocompatible solutions experienced a
mean reduction of Uvol of 0.30 l day1 (0.08) and a reduction
of nCrCl of 22.4 l week1 (0.49; both Po0.0001).
The difference in DnCrCl between standard and biocom-
patible groups in our study was 6.5 l week1 (with a
calculated s.e. of 6 l week1). On the basis of these results, the
probability of an actual difference in DnCrCl being greater
than the preset clinical significance of 410 l week1
(1 ml min1) was o0.001.
The difference in the DUvol (between standard and
biocompatible) in this study was 0.07 l day1 (s.e. was
0.12 l day1). We conducted non-inferiority analysis using
these results and the probability that biocompatible solutions
would protect Uvol by 40.3 l day1 was found to be o0.03.
Surrogates for fluid volume status, concomitant medications
The weight and clinic blood pressure readings at the time of
24-h urine collections (months 3 and 12) were not
statistically significantly different. The mean (s.e.m.) weight
at the time of the month 3 urine collections for the standard
group was 70.1 kg (2.1), and it was 69.4 kg (2.3) for the
biocompatible group (P¼NS). There was also no statistically
significant difference in the mean weights at the month 12
visit; 71.6 (2.7) and 69.9 kg (2.3), respectively. Similarly, there
were no intergroup differences in the lying or standing blood
pressure (mean systolic, diastolic or mean arterial pressure
(MAP)) at either month 3 or 12. The mean (s.e.m.) standing
blood pressure at month 3 for S: 132 (4)/80 (2), MAP: 97 mm
Hg (2) vs B: 129 (3)/79 (2), MAP 96 mm Hg (2); and at
month 12 for S: 130 (4)/79 (2), MAP 96 (2) vs B: 129 (4)/77
(2), MAP 94 mm Hg (2).
There were also no differences in the use of loop diuretics.
The proportion of patients prescribed a loop diuretic at
months 3 and 12 were the same, as was the mean dose
prescribed (month 3, S: 45% dose: 212 (30) vs B: 52%, dose:
186 mg day1 (27), month 12, S: 41% dose 212 mg day1
(37) vs B: 50%, dose: 200 mg day1 (27)). The peritonitis
treatment protocols used for both groups were identical—
gentamicin at the doses recommended by ISPD was used
empirically, but non-anuric patients were switched to
ceftazidime after culture and sensitivity results were made
available. Details of our peritonitis treatment protocol (and
results) are already published.12
Technique failure
Technique failure was defined as either death or transfer to
HD. The survival curves (data censored for transplantation
and transfer of patients to other PD units) of the two groups
are shown in Figure 4. There was no statistically significant
difference in the curves although follow-up was short and
event rate was relatively low.
Peritonitis rate
The peritonitis-free survival of patients (censored for death,
transfer to HD or other PD units, and transplantation) is
shown in Figure 5. There was no significant statistical
difference in the peritonitis-free survival curve between the
two groups. There were 19 peritonitis episodes suffered by
the patients using the standard solution, with an at-risk
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Figure 2 | Effect of biocompatible (B) vs standard (S) PD solutions
on RRF (mean of urea and nCrCl). Values are the mean (s.e.m.).
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Figure 3 | Effect of biocompatible (B) vs standard (S) PD solutions
on 24-h Uvol (mean/s.e.m.).
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period of 896 patient-months. This gave a peritonitis rate of
1:47.2 patient-months. There were 27 peritonitis episodes
suffered by the patients using the biocompatible solution
with an at-risk period of 973 patient-months. This gave a
peritonitis rate of 1:36.0 patient-months. There was no
statistically significant difference in peritonitis rate between
the two groups compared by w2 test.
Serum CRP concentrations
The mean serum CRP concentration at the start of PD was
same in both the groups (group S: 8.771.9 vs group B:
8.672.0 mg l1, P¼NS). At 12 months, CRP value for group
S was 9.773.3 vs 8.771.8 mg l1 (P¼NS) for group B
(Figure 6). There were no statistically significant changes
found within or between the groups by analysis of variance.
Peritoneal equilibrium test
There were 30 patients randomized to the biocompatible and
32 patients randomized to the standard groups that had two
PETs performed (Figure 7). In the biocompatible group, at 3
months the mean 4-h UF with the 2.26% glucose (glc) dwell
was 228 ml (38), D/P cr ratio was 0.71 (0.02), and D4/D0 glc
was 0.34 (0.01). There were no statistically significant
differences in these parameters in the standard group—UF
was 254 ml (37), D/P cr ratio was 0.71 (0.02), and D4/D0 glc
was 0.32 (0.02). There were no statistically significant changes
in the membrane function during the follow-up period.
After 12 months, biocompatible group patients had a 4-h UF
of 325 ml (39), D/P cr ratio was 0.70 (0.02), and D4/D0
glc was 0.35 (0.01). At follow-up, the standard group
patients had no statistically different PET results; 4-h UF
was 294 ml (28), D/P cr ratio was 0.71 (0.02), and D4/D0 glc
was 0.32 (0.01).
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Figure 4 | PD technique survival curve with censoring for
transplantation or transfer out to another unit on PD.
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Figure 5 | Peritonitis-free survival with censoring for
transplantation or transfer out to another unit on PD.
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Figure 6 | Effect of biocompatible (B) vs standard (S) PD solutions
on serum CRP concentration (mean/s.e.m.).
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Figure 7 | Effects of biocompatible (B) vs standard (S) PD
solutions on peritoneal membrane function (D/P cr ratio) and
UF during 4-h PET. Data indicated as box plots showing median,
quartiles, minimum, and maximum values.
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DISCUSSION
Our study does not support the hypothesis that the use of
biocompatible PD dialysis solutions protects residual kidney
function over a 9-month period, reduces peritonitis rates, or
improves technique survival. These results are perhaps
disappointing, considering the circumstantial evidence that
has been accumulating over the last few years. But perhaps
this should not be a surprise; Szeto et al.13 reported a smaller
study randomizing incident PD patients to a biocompatible
solution (Balance) against standard. They also could not detect
benefits on RRF or peritonitis rate over a 1-year period.
Insufficient power may explain why the study by Szeto et al.13
failed to detect an impact on RRF. However, our study was
adequately powered to test our primary hypothesis. Non-
inferiority (defined as a difference that is less than 1 ml min1
over 9 months) has been demonstrated statistically (Po0.0001).
Why should our results be different from those found in
the EuroBalance trial? There are several important differences
between the study designs. EuroBalance was a short-term
study (each treatment arm lasted 12 weeks) of crossover
design.10 Residual kidney function was assessed only as a
secondary end point. There were no surrogates for fluid
volume and in fact, dialysis UF increased with the
biocompatible solution Balance. It is therefore possible that
differences in the changes in Uvol was a reflection of different
fluid balance in the two groups.11
Our study also has important limitations. We wished to
examine the long-term consequence of using the newer
dialysis solutions. Our primary analyses were to compare the
changes in RRF (nCrCl and Uvol) over the study period.
However, this meant significant dropouts through technique
failure, death, and transplantation. In order to minimize
skewing of the month 3 data point in Figures 2 and 3 from
patients who did not complete the protocol, we only plotted
results from the ‘per protocol’ group. However, graphical
depiction of baseline RRF of ‘intention-to-treat’ group would
have been very similar; nCrCl for group S was 44.370.42 l
week1 vs 43.270.51 l week1 for group B. Moreover, the
results of intention-to-treat analysis comparing intergroup
differences in RRF at 12 months confirmed our findings.
Our study was designed only to examine change in RRF
between months 3 and 12. However, to confirm the
effectiveness of randomization, we calculated the estimated
GFR for the patients at the time dialysis was initiated.
However, because some patients had HD for substantial time
before the initiation of PD, we excluded patients that had
been on HD for greater than 30 days (we made the
assumption that decline in GFR on HD within 30 days
would be relatively small). We also recalculated starting
estimated glomerular filtration rate after excluding all
patients that needed HD. Both analysis showed that starting
renal functions were similar in the two groups, confirming
the effectiveness of the randomization process.
We also acknowledge that our study was not blinded, but
we provide weight, blood pressure, and diuretic usage data to
show that there were no obvious biases in our treatment.
It is also possible to criticize our study design. To properly
examine renal protection, it can be argued that it would be
inappropriate to include patients who are anuric at initial
assessment (month 3). However, recruitment into the study
was at PD initiation, and therefore we were unable to predict
those who would be anuric (Uvolo200 ml day1) after 3
months. Nevertheless, to address this issue, we have
reanalyzed our data excluding patients who had 24-h urine
output less than 200 ml day1 at month 3. There were still
no significant differences in DnCrCl (group B: 27.275.2
vs group S: 17.373.6 l week1) and Uvol (group B:
0.3770.08 vs group S: 0.4070.10 l day1). We could, and
perhaps should have measured baseline RRF by 24-h
urine collection at the time of PD initiation. However, fluid
balance is likely to be compromised at the start of dialysis and
many patients had prior exposure to HD before PD. We
know these factors can influence renal function and we
therefore decided to study the change in RRF after a period of
stabilization.
This study also gave results different from that by Szeto
et al.,13 who showed in their similar randomized study that
biomarkers of inflammation were reduced in patients treated
with Balance over a 1-year period. There are key differences
between the studies. ‘Ultrasensitive’ assays for CRP were not
available to us. Nevertheless, we believe our data remain valid
as a similar CRP assay was used and was found to be an
independent marker of atherosclerotic disease in this group
of patients.14 Moreover, we have previously shown that
treatment with 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) appeared to significantly
decrease CRP measured by this assay.15 We also provided
baseline CRP readings to confirm successful randomization,
whereas in the Hong Kong study, it was assumed that the use
of biocompatible solutions resulted in divergence as early as
in month 3, but no baseline values were measured. It is also
important that our study was larger and we took precautions
to avoid the effect of coincidental, concurrent infections at
the time points when CRP was measured.
The data from Hong Kong were also interesting because
they provided biomarkers of mesothelial cell mass (PD
effluent concentrations of CA125 and hyaluronan). Although
there appeared to be differences in these biomarkers, they did
not attempt to demonstrate any functional differences in
peritoneal membrane function. We have examined PET results
and we were not able to demonstrate any difference in
peritoneal membrane function in the two groups (biocompa-
tible vs standard). It remains possible that a modified
standardized peritoneal assessment (SPA) test (that utilizes a
4-h 4.25%/3.86% glc dwell) provides more information on
membrane characteristics (e.g., sodium sieving) and may have
demonstrated differences between our two study groups.
Our results are perhaps disappointing for clinicians who
had hoped that the use of biocompatible solutions would
herald an important advance in the treatment of PD patients.
The experience of the South Koreans7 was encouraging but
it is important to note that their study showing possible
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survival benefits with the use of Balance compared with
standard solution has been criticized.11
More difficult to discount are the benefits demonstrated
in vitro on peritoneal cells, including neutrophil function16
and mesothelial cell viability.3,17 There are also human
adult18,19 and children20 studies, as well as an in vivo animal
study2 that have demonstrated increases in Ca125 levels
(a marker of mesothelial cell mass) or less denudation of
mesothelial cells with the use of biocompatible solutions.
However, it remains to be proven if these effects translate into
benefit for the patients in real life when other factors such as
low-grade infection/catheter colonization and technique
burnout may be more dominant determinants of the success
of PD for the individual.
Finally, it should be noted that our PD unit used PD
solutions from two different companies. Patients were
allocated depending on individual assessment to determine
which connectology would be most appropriate. However,
the number of patients using Fresenius StaySafe solutions was
too small to allow subgroup analyses to determine differences
between the solutions and connectology from the different
companies.
This study has shown that the clinical outcomes (residual
kidney function, peritoneal membrane function, technique
survival, and peritonitis rates) were the same, irrespective of
standard or biocompatible PD solutions. However, it does
not mean that these newer biocompatible solutions are not
useful. They are particularly helpful for patients who
experience pain during a dialysis exchange. Moreover, we
readily acknowledge that our study was underpowered to
examine the impact biocompatible solutions might have on
peritonitis and technique survival. Rippe et al.18 also failed to
demonstrate improvements in peritonitis in a similarly sized
study; larger studies will be needed to demonstrate such
clinical advantages. It is also important that large, well-
designed, randomized controlled studies are conducted to
determine if particular genotypes and/or phenotypes of
patients gain clinical benefits.
MATERIALS AND METHODS
The study was approved by the East London and the City Research
Ethics Committee. We recruited incident patients starting PD at our
unit between January 2004 and December 2005. Our PD program
consists of approximately 230 patients at a given time. Approxi-
mately 60% of all patients are established on CAPD. The systems
used during the study period were as follows: UV Compact (Baxter,
15%), MiniSolo (Baxter, 70%), or StaySafe (Fresenius, 15%).
Patients undergoing APD used the HomeChoice (Baxter) machine.
Physioneal (Baxter) is not available for the UV Flash Compact
(Baxter) system, and patients who were felt to be most suited to this
system were excluded from recruitment.
Patients who consented were randomized to the standard
solution (Dianeal or StaySafe standard depending on the connecto-
logy that was felt to be best suited to the individual) or the
equivalent biocompatible solution (Physioneal or Balance), and
were trained to perform CAPD or APD by the same team of nursing
staff. Use of Icodextrin (Extraneal; Baxter) and Nutrineal (Baxter)
was freely available for both groups of patients using the Baxter
connectology; 82.6% of prevalent patients in our unit were using
Extraneal (72.9% CAPD and 94.1% APD). Although amino-
acid-based solution (Nutrineal) was available for all patients on
the Baxter systems, it was prescribed infrequently (o5%).
Baseline clinical data were recorded by patient chart review.
These included age, sex, underlying renal disease, and PD regimen.
A panel of comorbid conditions, including coronary artery disease,
heart failure, peripheral vascular disease, cerebrovascular disease,
chronic pulmonary disease, malignancy, heart failure, liver disease,
and diabetes mellitus was also recorded simultaneously during clinic
consultation for submission to UK Renal Registry. The clinician in
charge of the patient care also assigned the Karnofsky score at the
time of clinic visits. Patient weight and blood pressure details were
collected from patient diaries and clinic visits.
Residual renal function (defined by Uvol and the mean of urea
and nCrCl) was assessed by 24-h urine collection and blood
sampling at approximately 3 months, and as close to the anniversary
of starting PD as possible (timed to coincide with routine clinic
appointments, but delayed if within 30 days of peritonitis or other
serious reversible intercurrent illness). We also estimated GFR from
the last set of blood test performed prior to the start of dialysis using
the Cockroft–Gault calculation. Estimated GFR at time of end-stage
renal failure (ESRF) was not used for analysis of change in residual
kidney function, but merely to demonstrate the effectiveness of
randomization. Peritonitis rates and technique survival (defined as
death or transfer to HD censored for transplantation or transfer to
another PD unit) were recorded. The nearest serum CRP
concentration values measured as part of standard care (routinely
performed monthly and as clinically indicated) nearest to months 0,
3, 6, and 12 were collected. If there were more than one reading for
the month, the lowest value was selected to avoid peritonitis or
infections confounding the interpretation. Formal PETs were
performed at 3 months after starting PD and 12 months later.
These tests were delayed if within 30 days of peritonitis or if
clinically unstable. Results were analyzed using the commercially
available computer software package Renalsoft (Baxter Healthcare,
Compton, UK).
Biochemistry analysis
Biochemical tests were performed in our hospital laboratory using
Roche modular units analyser (F Hoffmann-La Roche Ltd, Basel,
Switzerland). Serum CRP concentrations were analyzed by the
immunoturbidimetric method. (Olympus Diagnostics, Hamburg,
Germany). For statistical analysis, CRP readings that were reported
to be within the normal range for the general population
(o5 mg l1) were assigned the value of 0. Indirect ion-selective
electrode methods were used for electrolyte levels, and the
phosphoenol pyruvate (PEP) method was used for measuring
bicarbonate levels.
Diagnosis of peritonitis
Diagnosis of peritonitis was in accordance with the ISPD guidelines.
Gram staining and culture were performed in all the cases. Effluent
was obtained from CAPD and APD patients after a minimum of 2-h
dwell. Samples were sent immediately for microbiological assess-
ment that included Gram staining, microscopy for cell count, and
culture on Blood and MacConkey agar in CO2 at 371C for 48 h. Two
10-ml samples were also inoculated into aerobic and anerobic blood
culture broth (BacT/ALERT Biomerieux Inc., Durham, NC, USA).
This was continually monitored for bacterial growth using the
automated BacT/Alert system for 4 days.
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Statistics
The primary end point for this study was changes in RRF defined by
24-h Uvol and nCrCl. Therefore, this analysis (paired t-test) was
limited to patients who underwent the two assessment points at 3
and 12 months (per protocol analysis). However, we also conducted
an intention-to-treat analysis using unpaired t-tests, comparing the
mean RRF at months 3 vs 12 within each group. The safety analyses
(secondary end points described above) were conducted on the full
data set.
The sample size estimate was based on the EuroBalance study.
In this study, the use of standard solutions for 12 weeks after the
use of Balance resulted in approximately 25% reduction in urinary
creatinine clearance. We therefore predicted that over a 9-month
follow-up period, use of standard solution would lead to at least
60% reduction in RRF. We calculated the power of the study based
on the hypothesis that use of biocompatible solutions would prevent
an absolute 30% loss of RRF compared with standard solutions.
Using a 1:1 ratio for randomization, a total of 42 patients in each
group were found to require 80% power to show this difference,
using Student’s t-test with a type 1 error of 0.05.
Separate analysis for non-inferiority was also performed for
the primary end points. We have predefined that non-inferiority
would be declared if the use of biocompatible solutions resulted in
the preservation of RRF (normalized mean of creatinine and urea
clearance) of less than 1 ml min1 compared with the standard
solution patients, over the study period. Similarly, we defined that a
clinically significant protection of urine output would be
300 ml day1 greater than the control group.
Kaplan–Meier PD survival curves were plotted with censoring for
transplantation. Peritonitis data analysis was performed in the
following two ways: peritonitis-free survival curves were plotted and
absolute peritonitis rates were compared by w2 test.
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